Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose furmonertinib first-line study in EGFR L858R-mutant advanced NSCLC
ChiCTR2200060897Phase 2Completed
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Started Sep 2022; status: completed.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200060897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060897.